0
bioAffinity Technologies, Inc. Banner Image

bioAffinity Technologies, Inc.

  • Ticker BIAF
    Exchange NASDAQ More
  • Industry Diagnostic Substances More
  • Sector Healthcare More
bioAffinity Technologies, Inc. Logo Image
  • 11-50 Employees
  • Based in San Antonio, Texas
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath® Lung is marketed as a laboratory developed test (LDT) by PrecisionMore Pathology Services. OncoSelect® Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio.
bioAffinity Technologies, Inc.

Most Recent Annual Report

bioAffinity Technologies, Inc.
MOST RECENT 2022 Annual Report and Form 10K
bioAffinity Technologies, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!